These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 38574400)
41. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. Weaver NA; Doeven T; Barkhof F; Biesbroek JM; Groeneveld ON; Kuijf HJ; Prins ND; Scheltens P; Teunissen CE; van der Flier WM; Biessels GJ; Neurobiol Aging; 2019 Dec; 84():225-234. PubMed ID: 31500909 [TBL] [Abstract][Full Text] [Related]
42. Contributions of amyloid beta and cerebral small vessel disease in clinical decline. Moonen JEF; Haan R; Bos I; Teunissen C; van de Giessen E; Tomassen J; den Braber A; van der Landen SM; de Geus EJC; Legdeur N; van Harten AC; Trieu C; de Boer C; Kroeze L; Barkhof F; Visser PJ; van der Flier WM Alzheimers Dement; 2024 Mar; 20(3):1868-1880. PubMed ID: 38146222 [TBL] [Abstract][Full Text] [Related]
43. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773 [TBL] [Abstract][Full Text] [Related]
44. Differential effects of white matter hyperintensities and regional amyloid deposition on regional cortical thickness. Tan CH; Chew J; Zhang L; Gulyás B; Chen C; Neurobiol Aging; 2022 Jul; 115():12-19. PubMed ID: 35453034 [TBL] [Abstract][Full Text] [Related]
45. White matter hyperintensities: relationship to amyloid and tau burden. Graff-Radford J; Arenaza-Urquijo EM; Knopman DS; Schwarz CG; Brown RD; Rabinstein AA; Gunter JL; Senjem ML; Przybelski SA; Lesnick T; Ward C; Mielke MM; Lowe VJ; Petersen RC; Kremers WK; Kantarci K; Jack CR; Vemuri P Brain; 2019 Aug; 142(8):2483-2491. PubMed ID: 31199475 [TBL] [Abstract][Full Text] [Related]
46. Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies. Thal DR; Attems J; Ewers M J Alzheimers Dis; 2014; 42 Suppl 4():S421-9. PubMed ID: 25227313 [TBL] [Abstract][Full Text] [Related]
47. Determinants and Temporal Dynamics of Cerebral Small Vessel Disease: 14-Year Follow-Up. Cai M; Jacob MA; van Loenen MR; Bergkamp M; Marques J; Norris DG; Duering M; Tuladhar AM; de Leeuw FE Stroke; 2022 Sep; 53(9):2789-2798. PubMed ID: 35506383 [TBL] [Abstract][Full Text] [Related]
48. Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Bos I; Verhey FR; Ramakers IHGB; Jacobs HIL; Soininen H; Freund-Levi Y; Hampel H; Tsolaki M; Wallin ÅK; van Buchem MA; Oleksik A; Verbeek MM; Olde Rikkert M; van der Flier WM; Scheltens P; Aalten P; Visser PJ; Vos SJB Alzheimers Res Ther; 2017 Dec; 9(1):101. PubMed ID: 29284531 [TBL] [Abstract][Full Text] [Related]
50. The relationship between amyloid pathology, cerebral small vessel disease, glymphatic dysfunction, and cognition: a study based on Alzheimer's disease continuum participants. Hong H; Hong L; Luo X; Zeng Q; Li K; Wang S; Jiaerken Y; Zhang R; Yu X; Zhang Y; Lei C; Liu Z; Chen Y; Huang P; Zhang M; Alzheimers Res Ther; 2024 Feb; 16(1):43. PubMed ID: 38378607 [TBL] [Abstract][Full Text] [Related]